Drug intelligence / Profile preview

EN002-gel

Development stage: Unknown
Lead developer: Enkang Pharmaceutical Technology
Modality: Small Molecules
Administration: Topical

Overview

EN002-gel is an investigational small molecule topical gel developed by EnKang Pharmaceuticals for the treatment of non-melanoma skin cancers and precancerous skin lesions. It acts as a DNA replication initiation proteins (DRIPs) inhibitor, specifically targeting the MCM7 protein (DNA replication licensing factor MCM7). By inhibiting MCM7, the drug aims to disrupt the replication process in malignant or precancerous cells. It is currently being evaluated in Phase I-II clinical trials in Australia for conditions including basal cell carcinoma, Bowen's disease, actinic keratosis, and squamous cell carcinoma of the skin.

Targets

MCM7 (DNA replication licensing factor MCM7)

Beyond the preview

Go deeper on EN002-gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EN002-gel.

Explore the full profile